Curaleaf Holdings (CURLF) Non-Current Deffered Revenue (2022 - 2024)
Curaleaf Holdings (CURLF) posted quarterly Non-Current Deffered Revenue of $2.0 million for Q4 2024, down 90.61% year-on-year from $21.3 million in Q1 2024, and down 91.58% on a QoQ basis from $23.7 million in Q3 2024.
Curaleaf Holdings (CURLF) Non-Current Deffered Revenue (2022 - 2024) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Non-Current Deffered Revenue for 3 consecutive years, with $2.0 million the latest figure, recorded in Q4 2024.
- Quarterly Non-Current Deffered Revenue fell 90.61% year-over-year to $2.0 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $2.0 million (down 90.61% YoY) and the FY2024 annual result came in at $2.0 million, down 90.61% from the prior year.
- Non-Current Deffered Revenue fell to $2.0 million in Q4 2024 per CURLF's latest filing, from $23.7 million in the prior quarter.
- Over the last five years, Non-Current Deffered Revenue for CURLF reached as high as $40.2 million in Q2 2023 and fell as low as $2.0 million in Q4 2024.
- A 3-year average of $26.8 million and a median of $23.7 million in 2024 frame the typical range for Non-Current Deffered Revenue.
- The largest YoY upside for Non-Current Deffered Revenue was 40.96% in 2024 against a maximum downside of 90.61% in 2024.
- Year by year, Non-Current Deffered Revenue stood at $36.9 million in 2022, then sank by 42.18% to $21.3 million in 2023, then sank by 90.61% to $2.0 million in 2024.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $2.0 million, $23.7 million, and $22.9 million for Q4 2024, Q3 2024, and Q2 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 2.00 Mn |
| Sep 30, 2024 | 23.75 Mn |
| Jun 30, 2024 | 22.93 Mn |
| Dec 31, 2023 | 21.31 Mn |
| Sep 30, 2023 | 40.22 Mn |
| Jun 30, 2023 | 40.22 Mn |
| Dec 31, 2022 | 36.85 Mn |